123 related articles for article (PubMed ID: 16472215)
1. Function oriented synthesis: the design, synthesis, PKC binding and translocation activity of a new bryostatin analog.
Wender PA; Baryza JL; Brenner SE; Clarke MO; Craske ML; Horan JC; Meyer T
Curr Drug Discov Technol; 2004 Jan; 1(1):1-11. PubMed ID: 16472215
[TBL] [Abstract][Full Text] [Related]
2. Simplified analogs of bryostatin with anticancer activity display greater potency for translocation of PKCdelta-GFP.
Baryza JL; Brenner SE; Craske ML; Meyer T; Wender PA
Chem Biol; 2004 Sep; 11(9):1261-7. PubMed ID: 15380186
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of a potent, PKC selective, B-ring analog of bryostatin.
Wender PA; Verma VA
Org Lett; 2006 Apr; 8(9):1893-6. PubMed ID: 16623578
[TBL] [Abstract][Full Text] [Related]
4. Role of the A-ring of bryostatin analogues in PKC binding: synthesis and initial biological evaluation of new A-ring-modified bryologs.
Wender PA; Clarke MO; Horan JC
Org Lett; 2005 May; 7(10):1995-8. PubMed ID: 15876038
[TBL] [Abstract][Full Text] [Related]
5. The rational design of potential chemotherapeutic agents: synthesis of bryostatin analogues.
Wender PA; Hinkle KW; Koehler MF; Lippa B
Med Res Rev; 1999 Sep; 19(5):388-407. PubMed ID: 10502742
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and evaluation of potent bryostatin analogs that modulate PKC translocation selectivity.
Wender PA; Baryza JL; Brenner SE; DeChristopher BA; Loy BA; Schrier AJ; Verma VA
Proc Natl Acad Sci U S A; 2011 Apr; 108(17):6721-6. PubMed ID: 21415363
[TBL] [Abstract][Full Text] [Related]
7. The design, computer modeling, solution structure, and biological evaluation of synthetic analogs of bryostatin 1.
Wender PA; DeBrabander J; Harran PG; Jimenez JM; Koehler MF; Lippa B; Park CM; Siedenbiedel C; Pettit GR
Proc Natl Acad Sci U S A; 1998 Jun; 95(12):6624-9. PubMed ID: 9618462
[TBL] [Abstract][Full Text] [Related]
8. Function-Oriented Synthesis: Design, Synthesis, and Evaluation of Highly Simplified Bryostatin Analogues.
Wender PA; Sloane JL; Luu-Nguyen QH; Ogawa Y; Shimizu AJ; Ryckbosch SM; Tyler JH; Hardman C
J Org Chem; 2020 Dec; 85(23):15116-15128. PubMed ID: 33200928
[TBL] [Abstract][Full Text] [Related]
9. Biological profile of the less lipophilic and synthetically more accessible bryostatin 7 closely resembles that of bryostatin 1.
Kedei N; Lewin NE; Géczy T; Selezneva J; Braun DC; Chen J; Herrmann MA; Heldman MR; Lim L; Mannan P; Garfield SH; Poudel YB; Cummins TJ; Rudra A; Blumberg PM; Keck GE
ACS Chem Biol; 2013 Apr; 8(4):767-77. PubMed ID: 23369356
[TBL] [Abstract][Full Text] [Related]
10. The role of protein kinase C isoenzymes in the growth inhibition caused by bryostatin 1 in human A549 lung and MCF-7 breast carcinoma cells.
Stanwell C; Gescher A; Bradshaw TD; Pettit GR
Int J Cancer; 1994 Feb; 56(4):585-92. PubMed ID: 8112895
[TBL] [Abstract][Full Text] [Related]
11. The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: dissociation of activities using 26-epi-bryostatin 1.
Szallasi Z; Du L; Levine R; Lewin NE; Nguyen PN; Williams MD; Pettit GR; Blumberg PM
Cancer Res; 1996 May; 56(9):2105-11. PubMed ID: 8616857
[TBL] [Abstract][Full Text] [Related]
12. Total synthesis and initial biological evaluation of new B-ring-modified bryostatin analogs.
Wender PA; Horan JC; Verma VA
Org Lett; 2006 Nov; 8(23):5299-302. PubMed ID: 17078702
[TBL] [Abstract][Full Text] [Related]
13. Modulation of protein kinase C activity and calcium-sensitive isoform expression in human myeloid leukemia cells by bryostatin 1: relationship to differentiation and ara-C-induced apoptosis.
Grant S; Turner AJ; Freemerman AJ; Wang Z; Kramer L; Jarvis WD
Exp Cell Res; 1996 Oct; 228(1):65-75. PubMed ID: 8892972
[TBL] [Abstract][Full Text] [Related]
14. Bryostatin 1 protects protein kinase C-delta from down-regulation in mouse keratinocytes in parallel with its inhibition of phorbol ester-induced differentiation.
Szallasi Z; Denning MF; Smith CB; Dlugosz AA; Yuspa SH; Pettit GR; Blumberg PM
Mol Pharmacol; 1994 Nov; 46(5):840-50. PubMed ID: 7969070
[TBL] [Abstract][Full Text] [Related]
15. Binding of [3H]bryostatin 4 to protein kinase C.
Lewin NE; Dell'Aquila ML; Pettit GR; Blumberg PM; Warren BS
Biochem Pharmacol; 1992 May; 43(9):2007-14. PubMed ID: 1596288
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of the anti-chikungunya virus activity of novel bryostatin analogs confirms the existence of a PKC-independent mechanism.
Abdelnabi R; Staveness D; Near KE; Wender PA; Delang L; Neyts J; Leyssen P
Biochem Pharmacol; 2016 Nov; 120():15-21. PubMed ID: 27664855
[TBL] [Abstract][Full Text] [Related]
17. Differential roles of the tandem C1 domains of protein kinase C delta in the biphasic down-regulation induced by bryostatin 1.
Lorenzo PS; Bögi K; Hughes KM; Beheshti M; Bhattacharyya D; Garfield SH; Pettit GR; Blumberg PM
Cancer Res; 1999 Dec; 59(24):6137-44. PubMed ID: 10626804
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of cisplatin sensitivity of cisplatin-resistant human cervical carcinoma cells by bryostatin 1.
Mohanty S; Huang J; Basu A
Clin Cancer Res; 2005 Sep; 11(18):6730-7. PubMed ID: 16166454
[TBL] [Abstract][Full Text] [Related]
19. The design, synthesis, and evaluation of C7 diversified bryostatin analogs reveals a hot spot for PKC affinity.
Wender PA; Verma VA
Org Lett; 2008 Aug; 10(15):3331-4. PubMed ID: 18588309
[TBL] [Abstract][Full Text] [Related]
20. The transient increase of tight junction permeability induced by bryostatin 1 correlates with rapid downregulation of protein kinase C-alpha.
Clarke H; Ginanni N; Laughlin KV; Smith JB; Pettit GR; Mullin JM
Exp Cell Res; 2000 Nov; 261(1):239-49. PubMed ID: 11082294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
